Regeneron Pharma Stock Gains 7% After Dupixent Met Endpoints In Phase 3 Trial For COPD

Shares of Regeneron Pharmaceuticals, Inc. (REGN) gained 7% on Thursday morning after the company and Sanofi S.A. (SNYNF) said that a late-stage study of Dupixent to treat lung disease has met endpoints.

REGN is currently trading at $803.85, up $52.55 or 7.00%, on the Nasdaq. The stock opened its trading at $806.47 after closing Wednesday's trading at $751.30. The stock has traded between $538.01 and $812.69 in the past 52-week period.

Sanofi and Regeneron on Thursday said late-stage study of their Dupixent for the treatment of chronic obstructive pulmonary disease (COPD) met its primary as well as all key secondary endpoints.

In the Phase 3 study, treatment with Dupixent showed 30% reduction in exacerbations of COPD with significant improvements in lung function, quality of life and COPD respiratory symptoms, in people with uncontrolled COPD and evidence of type 2 inflammation, the company said.

Dupixent is approved in the U.S for multiple indications, including the treatment of atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis, and eosinophilic esophagitis. The drug is approved for one or more of these indications in the European Union and Japan and more than 60 countries.

For comments and feedback contact: editorial@rttnews.com

Business News

Invest in the Best Pharma Stocks by Subscribing to RTT Biotech Investor.
Follow RTT